Micro-Therapeutics launches new urological subsidiary:
This article was originally published in Clinica
Micro-Therapeutics has formed a subsidiary to examine the possibilities for its Embolyx technology in urology and gynaecology. The new company, called Genyx Medical will be run by CEO Thomas Berryman, who is currently CFO of Micro-Therapeutics. Genyx will seek an initial round of financing. Micro-Therapeutics is backed by Guidant (see Clinica 784, p9). Embolyx is a biocompatible polymer dissolved in a solvent carrier, which rapidly precipitates as a solid in contact with body fluids. The new company plans to develop the product for urinary urge incontinence.